Compare VERA & STEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VERA | STEW |
|---|---|---|
| Founded | 2016 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2021 | N/A |
| Metric | VERA | STEW |
|---|---|---|
| Price | $46.59 | $18.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $76.60 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 84.5K |
| Earning Date | 02-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.71% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.44 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.34 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.53 | $11.97 |
| 52 Week High | $56.05 | $14.94 |
| Indicator | VERA | STEW |
|---|---|---|
| Relative Strength Index (RSI) | 50.00 | 47.51 |
| Support Level | $45.02 | $18.21 |
| Resistance Level | $49.75 | $18.57 |
| Average True Range (ATR) | 2.51 | 0.16 |
| MACD | -0.98 | -0.04 |
| Stochastic Oscillator | 18.54 | 11.91 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.